Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  ISIS Pharmaceuticals, Inc.    ISIS

 SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2016 279 M
EBIT 2016 -101 M
Net income 2016 -135 M
Finance 2016 64,3 M
Yield 2016 -
Sales 2017 355 M
EBIT 2017 -64,3 M
Net income 2017 -99,4 M
Finance 2017 97,7 M
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017
EV / Sales2016 20,1x
EV / Sales2017 15,7x
Capitalization 5 689 M
More Financials
Company
Ionis Pharmaceuticals, Inc. engages in the development and commercialization of antisense drug discovery.It operates its business through the Ionis Core and Akea Therapeutics segments.The Ionis Core segment involves a a novel drug discovery platform generate a broad pipeline of drugs.The Akea... 
Sector
Biotechnology & Medical Research
Calendar
02/28 | 05:30pmEarnings Call
More about the company
Surperformance© ratings of ISIS Pharmaceuticals, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on ISIS PHARMACEUTICALS, INC.
02/17 IONIS PHARMACEUTICALS INC : Blog Coverage Ionis Pharma Closed on its Collaborati..
02/16 IONIS PHARMACEUTICALS : IONS) Down on Novartis Deal
02/16 IONIS PHARMACEUTICALS : and Akcea Close on Strategic Collaboration with Global P..
02/16 IONIS PHARMACEUTICALS INC : Entry into a Material Definitive Agreement, Financia..
02/15 IONIS PHARMACEUTICALS : to Hold 2016 Financial Results Conference Call
02/14 IONIS PHARMACEUTICALS : Earns $75 Million from Bayer for Advancing -FXI Rx and -..
02/13 IONIS PHARMACEUTICALS : Publishes Papers on the Analysis of an Integrated Safety..
02/09 IONIS PHARMACEUTICALS : Earns $5 Million Milestone Payment from Biogen for Advan..
02/02 IONIS PHARMACEUTICALS : Earns $5 Million Milestone Payment from Biogen for Advan..
02/01 IONIS PHARMACEUTICALS : to Present at Upcoming Investor Conferences
More news
Sector news : Biotechnology & Medical Research - NEC
02:48pDJBristol-Myers Expands Board, Boosts Buybacks Amid Activist Pressure
02/16 How Sanofi lost out to J&J in $30 billion battle for Actelion
02/14 Gilead challenges GSK with strong HIV drug data
02/13 TEVA PHARMACEUTICAL INDUSTRIES : seeks CEO with pharma background to lead recove..
02/09DJAppeals Court Allows Sanofi, Regeneron to Continue Selling Cholesterol Drug
More sector news : Biotechnology & Medical Research - NEC
4-Traders Strategies on ISIS PHARMACEUTICALS, INC. 
2014A resistance as obstacle
More Strategies
News from SeekingAlpha
2015 Game Plan For The Week - Cramer's Mad Money (12/18/15)
2015 PREMARKET BIOTECH DIGEST : Portola's Milestone, Shkreli Resigns, BioMarin DMD Dr..
2015 Isis Pharma has had enough, name changed to Ionis Pharmaceuticals
2015 Bear Afoot? No Recession Needed For A Possible Sighting
2015 PREMARKET BIOTECH DIGEST : Gilead's Upside, Shire-Baxalta Deal, ARIAD Lowers Gui..
Advertisement
Chart ISIS PHARMACEUTICALS, INC.
Duration : Period :
ISIS Pharmaceuticals, Inc. Technical Analysis Chart | ISIS | US4643301090 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus HOLD
Number of Analysts 13
Average target price 46,5 $
Spread / Average Target -0,94%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Stanley T. Crooke Chairman, President & Chief Executive Officer
B. Lynne Parshall Chief Operating Officer & Director
Elizabeth L. Hougen Chief Financial Officer & Senior VP-Finance
Joseph H. Wender Independent Director
Frederick T. Muto Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ISIS PHARMACEUTICALS, ..-6.12%5 689
INCYTE CORPORATION20.17%22 822
QUINTILES IMS HOLDINGS..0.92%18 091
CELLTRION, INC.--.--%10 773
LONZA GROUP AG1.87%10 358
SEATTLE GENETICS, INC.24.12%9 272
More Results